Publications by authors named "A Aicher"
Pancreatic ductal adenocarcinoma (PDAC) is a highly metastatic and lethal disease. Gasdermins are primarily associated with necrosis via membrane permeabilization and pyroptosis, a lytic pro-inflammatory type of cell death. In this study, GSDMC upregulation during PDAC progression is reported.
View Article and Find Full Text PDFPancreatic ductal adenocarcinoma (PDAC) poses significant clinical challenges, often presenting as unresectable with limited biopsy options. Here, we show that circulating tumor cells (CTCs) offer a promising alternative, serving as a "liquid biopsy" that enables the generation of in vitro 3D models and highly aggressive in vivo models for functional and molecular studies in advanced PDAC. Within the retrieved CTC pool (median 65 CTCs/5 mL), we identify a subset (median content 8.
View Article and Find Full Text PDFArticle Synopsis
- The study focuses on pancreatic ductal adenocarcinoma (PDAC) and how cancer stem cells (CSCs) contribute to its aggressive nature and resistance to therapies, particularly immune checkpoint inhibitors.
- Researchers used a mouse model and primary tumor cell lines to identify CSC populations and their immune evasion strategies, discovering that the gene peptidoglycan recognition protein 1 (PGLYRP1) is significantly overexpressed in these cells.
- The findings suggest PGLYRP1 plays a key role in helping CSCs evade immune responses, highlighting its potential as a new target for immunotherapy in PDAC patients.
Over the past two decades, advances in computational power and data availability combined with increased accessibility to pre-trained models have led to an exponential rise in machine learning (ML) publications. While ML may have the potential to transform healthcare, this sharp increase in ML research output without focus on methodological rigor and standard reporting guidelines has fueled a reproducibility crisis. In addition, the rapidly growing complexity of these models compromises their interpretability, which currently impedes their successful and widespread clinical adoption.
View Article and Find Full Text PDFArticle Synopsis
- Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive cancer partly driven by cancer stem cells (CSCs), and targeting the factors that contribute to CSC resilience, such as NR5A2, is critical for improving treatment options.
- *In research using patient-derived PDAC models, it was found that NR5A2 promotes cell growth in regular cancer cells and enhances stemness in CSCs by influencing key genes and metabolic pathways.
- *Importantly, the NR5A2 inhibitor Cpd3 was shown to make PDAC cells more sensitive to chemotherapy, leading to better treatment outcomes and the potential for long-term survival, with NR5A2/SOX2 levels serving as a predictor for treatment response